Screening neonatale esteso di malattie ereditarie rare: l’esperienza del Piemonte e della Valle d’Aosta

AUTORI

ABSTRACT

Impact of expanded newborn screening in the identification of hereditary diseases in two Italian regions (Piemonte e Valle d’Aosta

Newborn screening (NBS) is the most effective tool for the identification of serious health conditions as it allows early diagnosis and prompt treatment initiation. The screening center of Torino carries out screening for newborns from two Italian regions (Piemonte and Valled’Aosta) for Phenylketonuria (PKU), Congenital Hypothyroidism (CH), Galactosemia (GAL), Biotinidase deficiency (BTD), Cystic Fibrosis (CF), 36 Inborn Errors of Metabolism and Congenital Adrenal Hyperplasia (CAH). Expanded NBS (NBSE, Italian Law 167/2016) should be performed on all live births between 48-72 hours of life. Since May 2017, 165758 Dried Blood Spots were analyzed by time-resolved Immunofluorescence (Galactose, Biotinidase, Immunoreactive Trypsinogen, 17-hydroxy-Progesterone, Thyroid Stimulating Hormone), or by tandem mass spectrometry (simultaneous quantification of aminoacids and acylcarnitines). 378 diagnosis were made: 153 CH (42.5%); 88 CF (23.3%); 54 aminoacidopathies (14.3%); 29 BTD (7.7%); 24 fatty acid oxidation disorders (6.3%); 14 GAL (3.7%); 9 CAH (2.4%); 4 organic acidemias (1.1%); 3 urea cycle disorders (0.7%). Moreover, another five conditions have been identified: 237 heterozygous subjects; 108 subjects with transient impairment; 31 subjects with impairment acquired from maternal deficiency; 15 patients needed to continue the process of a differential diagnosis of the screened pathologies; 5 patients with acute neonatal onset of diseases not covered by the law. During this activity, the overall incidence of early diagnoses was of 1:438 newborns. The majority of these screening-positive newborns suffered from diseases with a high degree of risk of progression for which immediate therapeutic intervention and the adoption of preventive measures were required

BIBLIOGRAFIA

BIBLIOGRAFIA
1. Corbetta C. Le nuove frontiere dello screening neonatale: l’era della “tandem mass”. Biochim Clin 2009;33:205-12.
2. Andermann A, Blancquaert I, Beauchamp S, Déry V. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ 2008;86:317-9. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2647421/ (ultimo accesso: febbraio 2024)
3. Disposizioni in materia di accertamenti diagnostici neonatali obbligatori per la prevenzione e la cura delle malattie metaboliche ereditarie. Gazzetta Ufficiale della Repubblica Italiana: www.iss.it/documents/20126/0/LEGGE++19+agosto+2016+%2C+n.167.pdf/5aa3887e-865b-9e77-be30-32d0055aceae?t=1576842271001 (ultimo accesso: febbraio 2024)
4. Park KJ, Park S, Lee E, Park JH, Park JH, Park HD, et al. A population-based genomic study of inherited metabolic diseases detected through newborn screening. Ann Lab Med 2016;36:561-72.
5. Scriver CR. Garrod’s Croonian Lecture (1908) and the charter “Inborn Errors of Metabolism”: albinism, alkaptonuria, cystinuria, and pentosuria at age 100 in 2008. J Inherit Metab Dis 2008;31:580-98.
6. Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large population of newborn infants. Pediatrics 1963;32:338-43.
7. Werner SC, Acebedo G, Radichevich I. Rapid radioimmunoassay for both T4 e T3 in the same sample of human serum. J Clin Endocrinol Metab 1974;38:493-5.
8. Chace DH, Kalas TA, Naylor EW. Use of tandem mass spectrometry for multianalyte screening of dried blood specimens from newborns. Clin Chem 2003;49:1797-817.
9. Wilcken B, Wiley V et al. Screening newborns for inborn errors of metabolism by tandem mass spectrometry. N Engl J Med 2003;348:2304-12.
10. Sito SIMMESN: https://www.simmesn.it/it/societa/lo-screening-neonatale.html (ultimo accesso: febbraio 2024).
11. Bollettino Regione Piemonte: www.regione.piemonte.it/governo/bollettino/abbonati/2003/30/siste/00000030.htm (ultimo accesso: febbraio 2024).
12. Bollettino Regione Piemonte: www.regione.piemonte.it/governo/bollettino/abbonati/2017/09/attach/dgr_04667_830_13022017.pdf (ultimo accesso: febbraio 2024).
13. Progetto di screening Neonatale per la diagnosi precoce della Atrofia Muscolare Spinale 5q (SMA5q) nella popolazione neonatale del Piemonte-Valle D’Aosta (NeoSMA Piemonte-Valle D’Aosta), Citta della Salute e della Scienza di Torino https://www.ospedale.al.it/it/ricerca-formazione/sperimentazioni/progetto-screening-neonatale-per-diagnosi-precoce-atrofia-muscolare-spinale-5q-sma5q-nella (ultimo accesso: febbraio 2024).
14. Perkin Elmer – Revvity: https://resources.perkinelmer.com/corporate/pdfs/downloads/bro-newborn-screening-today-italian.pdf (ultimo accesso: febbraio 2024).
15. Sito SIMMESN: https://www.simmesn.it/it/societa/le-malattie-metaboliche.html (ultimo accesso: febbraio 2024).
16. GSP – Perkin Elmer: https://resources.perkinelmer.com/lab-solutions/resources/docs/bro_gsp-newborn-screening-system_us_1599-9793-1.pdf (ultimo accesso: febbraio 2024).
17. Ombrone D, Giocaliere E, Forni G, Malvagia S, la Marca G. Expanded newborn screening by mass spectrometry: New tests, future perspectives. Mass Spectrom Rev 2016;35:71-84.
18. Ruoppolo M, Malvagia S, Boenzi S, Carducci C, Dionisi-Vici C, Teofoli F et al. Expanded Newborn Screening in Italy Using Tandem Mass Spectrometry: Two Years of National Experience. Int J Neonatal Screen 2022;8:47.